Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296465 · ClinicalTrials.gov registry record · Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT00296465 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 132 participants.
The verdict
NCT00296465, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
This study will be performed in approximately 132 women with anovulatory/oligoovulatory infertility.
Interventions
- DRUG Clomiphene Citrate
- DRUG Pulsatile gonadotropin-releasing hormone (GnRH)
- DRUG Placebo Pulsatile GnRH
- DRUG Placebo Clomiphene Citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2005-02 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00296465
The ClinicalTrials.gov registry entry for NCT00296465 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Clomiphene Citrate is the first listed.
NCT00296465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00296465 about?
NCT00296465 is a clinical study titled "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH". This study will be performed in approximately 132 women with anovulatory/oligoovulatory infertility.
What is the current status of trial NCT00296465?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2005-02. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00296465?
The interventions under investigation include: Clomiphene Citrate (DRUG), Pulsatile gonadotropin-releasing hormone (GnRH) (DRUG), Placebo Pulsatile GnRH (DRUG), Placebo Clomiphene Citrate (DRUG).
Who is sponsoring clinical trial NCT00296465?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.